EMA Authorised: Mayzent (siponimod fumaric acid) — Novartis Europharm Limited

View source ↗

Summary

Mayzent (siponimod fumaric acid) has been authorised in the EU for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Novartis Europharm Limited. Decision date: 04/06/2026